Wells Fargo & Company Forecasts Strong Price Appreciation for Septerna (NASDAQ:SEPN) Stock

Septerna (NASDAQ:SEPN) had its price target raised by equities research analysts at Wells Fargo & Company from $28.00 to $48.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 66.49% from the stock’s current price.

Other equities analysts also recently issued reports about the stock. Zacks Research upgraded shares of Septerna from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. Truist Financial assumed coverage on shares of Septerna in a research report on Monday, December 15th. They issued a “buy” rating and a $34.00 price target for the company. Wall Street Zen cut Septerna from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 10th. Raymond James Financial began coverage on shares of Septerna in a research report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 price objective on the stock. Finally, JonesTrading assumed coverage on Septerna in a research report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Septerna has a consensus rating of “Moderate Buy” and a consensus price target of $38.00.

Septerna Stock Up 2.5%

Septerna stock opened at $28.83 on Tuesday. Septerna has a 12-month low of $4.66 and a 12-month high of $32.63. The business’s 50-day simple moving average is $26.91 and its 200 day simple moving average is $22.70. The stock has a market cap of $1.29 billion, a price-to-earnings ratio of -19.09 and a beta of 3.46.

Insider Activity at Septerna

In other news, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at $5,046,834.73. This represents a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Samira Shaikhly sold 70,453 shares of the business’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $28.10, for a total transaction of $1,979,729.30. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,283.30. The trade was a 98.89% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Deutsche Bank AG lifted its holdings in Septerna by 5.3% in the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after purchasing an additional 744 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in Septerna during the fourth quarter valued at $35,000. Covestor Ltd lifted its holdings in shares of Septerna by 55.8% in the 3rd quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock worth $107,000 after purchasing an additional 1,315 shares during the period. Finally, PharVision Advisers LLC boosted its holdings in shares of Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.